期刊
INTERNATIONAL JOURNAL OF STD & AIDS
卷 22, 期 5, 页码 294-295出版社
SAGE PUBLICATIONS LTD
DOI: 10.1258/ijsa.2009.009166
关键词
tipranavir; enfuvirtide; pregnancy; pharmacokinetics; HIV; mother-to-child transmission; antiretroviral therapy
The data on the use of tipranavir and enfuvirtide in pregnancy are very limited. We performed a pharmacokinetic profile in a pregnant woman with multidrug-resistant HIV-1 infection at 37 weeks gestation. Tipranavir levels were in the therapeutic range and the cord blood concentration at delivery was relatively high when compared with other protease inhibitors. No enfuvirtide was detected in the fetal compartment. Tipranavir and enfuvirtide were successfully used in pregnancy, but possible toxicities must be kept in mind.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据